MedPath

Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis

Phase 4
Completed
Conditions
Allergic Conjunctivitis
Interventions
Registration Number
NCT00534794
Lead Sponsor
Merck Sharp & Dohme LLC
Brief Summary

The purpose of this study is to compare the effects of two marked ocular anti-allergy medications in cat sensitive subjects with allergic conjunctivitis.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
79
Inclusion Criteria
  • Documented history of ocular allergy to cats.
  • Positive skin prick allergen reaction to cat dander.
Exclusion Criteria
  • Use of any topical or systemic corticosteroids, immunosuppressive agents, antihistamines, decongestants, NSAIDs, or asprin during the two weeks prior to enrollment into the study.
  • History of severe asthma, reactive airway disease or bronchial obstruction.
  • Ocular surgery or trauma in the last year.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PatadayPataday-
ElestatElestat-
Primary Outcome Measures
NameTimeMethod
Change in Ocular Itch Score From Baseline0 hours, 12 hours

Ocular itch was measured on a 0 (none) to 4 (severe itch with continual desire to rub eyes) scale. Negative values for change from baseline represent favorable outcomes.

Secondary Outcome Measures
NameTimeMethod
Ocular Comfort Score at 12 Hours12 hours

Ocular comfort was measured on a 0 (more uncomfortable) to 10 (more comfortable) scale.

Trial Locations

Locations (1)

Ophthalmic Consultants of Boston

🇺🇸

Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath